Regeneron Looks To Use CRISPR Inside/Outside The Liver With Intellia Pact

One option for the FDA going forward could be holding an advisory committee meeting on its safety concerns after Sarepta agreed to stop all shipments of its DMD gene therapy.

A new PBM reform package has familiar provisions, but stakeholders want it to move as a stand-alone bill, rather than as part of a larger legislative vehicle.

George Tidmarsh has extensive experience in the biopharmaceutical industry and led several drugs to FDA approval.

Innovator drug advocates argued that the number of patents asserted by industry is not too dissimilar to other fields. But should drugs be compared to golf balls?